BERLIN (dpa-AFX) - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and Merck KGaA (MKKGY, MRCG.DE, MRK.MI) announced that they have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP).
As per the terms of the deal, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck KGaA's antibody-conjugated LNP services. Merck KGaA has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and sublicenses.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
